Ocular Therapeutix (OCUL) Current Assets (2013 - 2026)
Ocular Therapeutix's quarterly Current Assets came in at $706.0 million in Q1 2026, up 82.1% year-on-year from $387.7 million in Q1 2025, and down 9.73% quarter-over-quarter from $782.1 million in Q4 2025.
Ocular Therapeutix has reported Current Assets for 14 years, with the latest figure at $706.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 82.1% year-over-year to $706.0 million; the trailing twelve-month figure through Mar 2026 stood at $706.0 million (up 82.1% YoY), and the FY2025 full-year result was $782.1 million, up 77.36% from the prior year.
- Current Assets for Q1 2026 stood at $706.0 million, down from $782.1 million in the prior quarter.
- The five-year high for Current Assets was $782.1 million in Q4 2025, with the low at $100.7 million in Q2 2023.
- Average Current Assets over 5 years is $342.4 million, with a median of $387.0 million recorded in 2025.
- Year-over-year, Current Assets slumped 38.64% in 2023 and soared 395.06% in 2024.
- Tracing OCUL's Current Assets over 5 years: stood at $129.6 million in 2022, then soared by 79.16% to $232.2 million in 2023, then jumped by 89.89% to $441.0 million in 2024, then soared by 77.36% to $782.1 million in 2025, then decreased by 9.73% to $706.0 million in 2026.
- The last three Current Assets figures came in at $706.0 million (Q1 2026), $782.1 million (Q4 2025), and $387.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 706.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 706.00 Mn |
| Dec 31, 2025 | 782.13 Mn |
| Sep 30, 2025 | 386.98 Mn |
| Jun 30, 2025 | 433.38 Mn |
| Mar 31, 2025 | 387.69 Mn |
| Dec 31, 2024 | 440.99 Mn |
| Sep 30, 2024 | 473.01 Mn |
| Jun 30, 2024 | 498.59 Mn |
| Mar 31, 2024 | 519.82 Mn |
| Dec 31, 2023 | 232.24 Mn |
| Sep 30, 2023 | 141.26 Mn |
| Jun 30, 2023 | 100.71 Mn |
| Mar 31, 2023 | 107.16 Mn |
| Dec 31, 2022 | 129.63 Mn |
| Sep 30, 2022 | 145.62 Mn |
| Jun 30, 2022 | 160.32 Mn |
| Mar 31, 2022 | 174.65 Mn |
| Dec 31, 2021 | 191.30 Mn |
| Sep 30, 2021 | 203.93 Mn |
| Jun 30, 2021 | 216.52 Mn |
| Mar 31, 2021 | 228.13 Mn |
| Dec 31, 2020 | 246.16 Mn |
| Sep 30, 2020 | 81.90 Mn |
| Jun 30, 2020 | 90.29 Mn |
| Mar 31, 2020 | 55.15 Mn |
| Dec 31, 2019 | 60.17 Mn |
| Sep 30, 2019 | 69.64 Mn |
| Jun 30, 2019 | 65.44 Mn |
| Mar 31, 2019 | 79.17 Mn |
| Dec 31, 2018 | 56.19 Mn |
| Sep 30, 2018 | 58.27 Mn |
| Jun 30, 2018 | 58.47 Mn |
| Mar 31, 2018 | 64.48 Mn |
| Dec 31, 2017 | 43.34 Mn |
| Sep 30, 2017 | 52.45 Mn |
| Jun 30, 2017 | 68.33 Mn |
| Mar 31, 2017 | 83.28 Mn |
| Dec 31, 2016 | 69.90 Mn |
| Sep 30, 2016 | 76.82 Mn |
| Jun 30, 2016 | 84.97 Mn |
| Mar 31, 2016 | 97.10 Mn |
| Dec 31, 2015 | 106.98 Mn |
| Sep 30, 2015 | 115.90 Mn |
| Jun 30, 2015 | 126.64 Mn |
| Mar 31, 2015 | 69.47 Mn |
| Dec 31, 2014 | 76.18 Mn |
| Sep 30, 2014 | 82.27 Mn |
| Jun 30, 2014 | 22.59 Mn |
| Dec 31, 2013 | 18.01 Mn |